Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P810006/S114

Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo

Integra LifeSciences Corporation · Decision date Jun 4, 2026

FDA DECISIONP810006/S114

What did the FDA decide?

FDA records P810006/S114 as a supplement to PMA P810006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 4, 2026.

FDA approval order statement

replacement of the current bacterial endotoxin testing (BET) methods, Gel Clot and Kinetic Turbidimetric, with the Chromogenic method performed on the Endosafe Nexgen-MCS system
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Jun 4, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P810006/S114
Regulatory pathway
PMA supplement
Product code
LMF
Decision code
OK30
Decision date
Jun 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, collagen based.

Product code
LMF
FDA device class
3

For the original device and its historical approval scope, see PMA P810006. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P810006/S114 received

    Application receipt date recorded by FDA.

  2. P810006/S113 · Related supplement

    Collastat Absorbable Collagen Hemostatic Sponge

  3. P810006/S114 · FDA decision

    30-Day Notice

  4. P810006/S115 · Related supplement

    Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo

Timeline entries are records held by MedtechLedger for P810006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P810006

Explore the linked device profile

Other records with product code LMF

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integra LifeSciences Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
311 Enterprise Dr., Planisboro, NJ, 08536

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records